Full Name
Ruth O'Regan, MD
Speaker Bio
Dr. Ruth O’Regan, M.D. is Chair of Medicine at the University of Rochester and Physician-in-Chief of Strong Memorial Hospital. A leading breast cancer researcher, she has held major leadership roles at the University of Wisconsin, Emory University, and the Big Ten Cancer Research Consortium. Her work focuses on therapy resistance, especially in triple-negative breast cancer.
Speaking At
GS1-07 - Adjuvant palbociclib in HR+/HER2- early breast cancer: Final protocol-planned analysis results from 5,761 patients in the randomized phase III PALLAS trial
GS2-02 - Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine monotherapy for ER+/ HER2- advanced / metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy
GS2-05 - Randomized comparisons of adjuvant exemestane + ovarian function suppression (OFS) vs tamoxifen + OFS vs tamoxifen in premenopausal women with HR+ early breast cancer: update of the TEXT and SOFT trials
GS3-10 - Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDKz, in combination with fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer
GS3-09A - Circulating Tumor Cells-driven choice of first line therapy for HR+ HER2- metastatic breast cancer
GS1-06 - Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial
GS1-09 - Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes
GS3-01A - EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: updated results by duration of prior CDK4/6i in metastatic setting
RF01-01 - SERENA-3: A randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary cancer
RF01-02 - A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy
RF01-03 - PARSIFAL-LONG: Extended follow-up of hormone receptor-positive/HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs letrozole and palbociclib in the PARSIFAL study
RF01-04 - Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification
RF01-06 - Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer
RF01-07 - The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC
RF01-08 - A randomized, open-label phase III trial Evaluating Low-Dose Vs standard-dose Olanzapine with triple Antiemetic therapy for Prevention of highly emetogenic chemotherapy- induced Nausea and vomiting in solid tumors (OLAnzaPiNE)
RF01-01 SERENA-3 - A randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary cancer (China)
RF01-02 - A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy (China)
RF01-03 - PARSIFAL-LONG: Extended follow-up of hormone receptor-positive/HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs letrozole and palbociclib in the PARSIFAL study (China)
RF01-04 - Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification (China)
RF01-06 - Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer (China)
RF01-07 - The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC (China)
RF01-08 - A randomized, open-label phase III trial Evaluating Low-Dose Vs standard-dose Olanzapine with triple Antiemetic therapy for Prevention of highly emetogenic chemotherapy- induced Nausea and vomiting in solid tumors (OLAnzaPiNE) (China)
GS2-05: Early Oncologic Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS: the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25).
GS2-06: Patient Reported Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS in the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25).
GS2-07: No axillary surgery versus axillary sentinel lymph node biopsy in patients with early invasive breast cancer and breast-conserving surgery: Final primary results of the Intergroup-Sentinel-Mamma (INSEMA) trial.
GS2-09: Overweight, obesity and prognosis in 206,904 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database.
ED4-02: Beyond hot flashes: Addressing unmet needs in menopause care after breast cancer Commentary by: Maryam Lustberg, MD, MPH
ED4-04: The Winding Road of MHT: Evidence, Messaging, and an Evidence Informed Approach to Discussing MHT with Women at Elevated Risk - Commentary by: Lisa Larkin, MD, FACP, MSCP, IF
ED4-05: Rethinking menopause and breast cancer: is it time to change practice? Commentary by: Maryam Lustberg, MD, MPH
RF2-01: Prognostic Markers in Residual Tumors after neoadjuvant chemotherapy (NACT) for Early Triple-negative Breast Cancer (TNBC) – a Pooled Analysis from nine Neoadjuvant GBG/AGO-B Trials Commentary by: Joseph Sparano, MD, FACP
RF2-02: Pooled analysis of the BrighTNess, CALGB 40603 (Alliance), and GeparSixto clinical trials identifies the impact of neoadjuvant carboplatin on pCR and survival in early-stage triple-negative breast cancer Commentary by: Joseph Sparano, MD, FACP
RF2-03: Adjuvant epirubicin plus cyclophosphamide followed by taxanes with or without carboplatin for early stage triple-negative breast cancer (RJBC 1501): a randomized controlled phase III trial Commentary by: Joseph Sparano, MD, FACP
RF2-04: Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high-risk early-stage triple-negative breast cancer (CITRINE): a phase 3 randomized trial Commentary by: Joseph Sparano, MD, FACP
RF2-06: Impact of Immune Checkpoint Inhibition (CPI) on Fertility in Young Women with Early Triple-Negative Breast Cancer (TNBC) receiving neoadjuvant Chemotherapy - Commentary by: Joseph Sparano, MD, FACP
RF2-07: Nodal disease burden in patients with clinically node - positive breast cancer undergoing tailored axillary surgery with or without axillary dissection in the neoadjuvant and upfront surgery setting - Commentary by: Joseph Sparano, MD, FACP
ED6-01: Moving on up: ADCs in early-stage breast cancer - Commentary by: Kevin Kalinsky, MD, MS, FASCO
GS1-01: Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer - Commentary by: Matteo Lambertini, MD, PhD
GS1-01 (J): Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer - Commentary by: Prof Eriko Tokunaga
GS1-03: Adjuvant aromatase inhibitor or tamoxifen in patients with hormone receptor-positive/HER2-positive early breast cancer: an exploratory analysis from the ALTTO (BIG 2-06) trial - Commentary by: Matteo Lambertini, MD, PhD
GS1-04 (J): Tumor infiltrating lymphocytes and pathologic complete response in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab - Commentary by: Prof Eriko Tokunaga
GS1-04: Tumor infiltrating lymphocytes and pathologic complete response in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab - Commentary by: Matteo Lambertini, MD, PhD
GS1-05: Prognostic and predictive associations of manual, digital and AI-derived tumor infiltrating lymphocytes-scoring: A retrospective analysis from the Phase III APHINITY trial - Commentary by: Matteo Lambertini, MD, PhD
GS1-06: Circulating tumor DNA (ctDNA) in human epidermal growth factor receptor 2-positive (HER2[+]) Early Breast Cancer (EBC): Translational analysis of PHERGain neoadjuvant tailored treatment study - Commentary by: Kevin Kalinsky, MD, MS, FASCO
GS1-06 (J) : Circulating tumor DNA (ctDNA) in human epidermal growth factor receptor 2-positive (HER2[+]) Early Breast Cancer (EBC): Translational analysis of PHERGain neoadjuvant tailored treatment study - Commentary by: Prof. Shigehira Saji
GS1-08 (J): Multimodal Artificial Intelligence (AI) Models Integrating Image, Clinical, and Molecular Data for Predicting Early and Late Breast Cancer Recurrence in TAILORx - Commentary by: Prof. Shigehira Saji
GS1-08: Multimodal Artificial Intelligence (AI) Models Integrating Image, Clinical, and Molecular Data for Predicting Early and Late Breast Cancer Recurrence in TAILORx - Commentary by: Joseph Sparano, MD, FACP
GS1-09 (J): Sacituzumab Govitecan vs. Chemotherapy as First Therapy After Endocrine Therapy in HR+/HER2- (IHC 0, 1+, 2+/ISH-) Metastatic Breast Cancer: Primary Results From ASCENT-07 Commentary by: Prof. Shigehira Saji
GS1-09: Sacituzumab Govitecan vs. Chemotherapy as First Therapy After Endocrine Therapy in HR+/HER2- (IHC 0, 1+, 2+/ISH-) Metastatic Breast Cancer: Primary Results From ASCENT-07 Commentary by: Kevin Kalinsky, MD, MS, FASCO
GS1-10: Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from Phase III lidERA Breast Cancer trial - Commentary by: Hope S. Rugo, MD
GS1-10 (J): Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from Phase III lidERA Breast Cancer trial - Commentary by: Prof. Shigehira Saji
GS1-11: lidERA and Advent of Adjuvant SERDs - Commentary by: Hope S. Rugo, MD
RF3-02: Gene Expression-based Subtyping of Early Triple-Negative Breast Cancer (TNBC) for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial - Commentary by: Peter Fasching, MD
RF3-04: Tumor-informed circulating tumor DNA analysis to assess molecular residual disease for prognosis and prediction of benefit from palbociclib in the PALLAS trial - Commentary by: Peter Fasching, MD
RF3-07: A Multimodal-Multitask Deep Learning Model Trained in NSABP B-42 and Validated in TAILORx for Late Distant Recurrence Risk in HR+ Early Breast Cancer - Commentary by: Peter Fasching, MD
RF6-01 (J): (T-DXd) vs (T-DM1) in patients with (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy: Interim analysis of DESTINY-Breast05 - Commentary by: Prof Eriko Tokunaga
RF6-01: (T-DXd) vs (T-DM1) in patients with (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy: Interim analysis of DESTINY-Breast05 - Commentary By: Giuseppe Curigliano, MD, PhD
RF6-02: (DB-11) safety: (T-DXd) alone or followed by (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC) - Commentary By: Giuseppe Curigliano, MD, PhD
RF6-02 (J): (DB-11) safety: (T-DXd) alone or followed by (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC) - Commentary by: Prof Eriko Tokunaga
RF6-03: Efficacy and safety of DP303c versus T-DM1 in HER2-positive advanced breast cancer: Interim analysis of a randomized, open-label, phase 3 trial - Commentary By: Giuseppe Curigliano, MD, PhD
RF6-06: DESTINY-Breast11 (DB-11) safety: (T-DXd) alone or followed (THP) vs dose-dense doxorubicin + anthracycline followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC) - Commentary By: Giuseppe Curigliano, MD, PhD
RF6-06 (J): (PROs) in DESTINY-Breast11: (NAT) with (T-DXd) alone or followed by (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC) - Commentary Prof Eriko Tokunaga By:
RF6-06: (PROs) in DESTINY-Breast11: (NAT) with (T-DXd) alone or followed by (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC) - Commentary By: Giuseppe Curigliano, MD, PhD
RF6-07: (T-DXd) + (P) vs (THP) for first-line (1L) treatment of patients with HER2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): patient-reported outcomes (PROs) from the DESTINY-Breast09 study - Commentary By: Giuseppe Curigliano, MD, PhD
GS1-10: Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from Phase III lidERA Breast Cancer trial - Commentary by: Agatha Reyes, MD
GS2-01 (J): More vs less invasive axillary staging in breast cancer patients converting from node-positive to node-negative through neoadjuvant chemotherapy - AXSANA/EUBREAST 3(R) primary analysis
GS2-01 (J): More vs less invasive axillary staging in breast cancer patients converting from node-positive to node-negative through neoadjuvant chemotherapy - AXSANA/EUBREAST 3(R) primary analysis - Prof Norikazu Masuda
GS2-01: More versus less invasive axillary surgical staging procedures in BC patients converting from a clinically node-+ to a clinically node-+ stage through NAC – Commentary by Sheldon Feldman, MD, FACS
GS2-02: Axillary surgery in breast cancer patients with one to three sentinel node macrometastases and breast-conserving therapy: Secondary results of the INSEMA trial - Commentary by Sheldon Feldman, MD, FACS
GS2-02 (J): Axillary surgery in breast cancer patients with one to three sentinel node macrometastases and breast-conserving therapy: Secondary results of the INSEMA trial - Commentary by Prof Norikazu Masuda
GS2-03: Insights of applied radiotherapy among patients undergoing breast-conserving surgery with or without axillary sentinel lymph node biopsy: secondary results from the INSEMA trial - Commentary by Sheldon Feldman, MD, FACS
GS2-03 (J): Insights of applied radiotherapy among patients undergoing breast-conserving surgery with or without axillary sentinel lymph node biopsy: secondary results from the INSEMA trial - Commentary by Prof Norikazu Masuda
GS2-05: Primary Results from the HR+/HER2- Cohort of TBCRC-053: A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer - Commentary by Sheldon Feldman, MD, FACS
GS2-07: Effect of Preoperative Breast MRI Staging on Local Regional Recurrence (LRR) in Early Stage Breast cancer: Alliance A011104/ACRIN 6694 - Commentary by Sheldon Feldman, MD, FACS
GS2-07 (J): Effect of Preoperative Breast MRI Staging on Local Regional Recurrence (LRR) in Early Stage Breast cancer: Alliance A011104/ACRIN 6694 - Commentary by Prof Yutaka Yamamoto
GS2-09 (J): The single-arm confirmatory trial of tamoxifen alone without surgery for low-risk DCIS of the breast with ER-positive HER2-negative (LORETTA trial: JCOG1505) - Commentary by Prof Hiroko Bando
GS2-09: The single-arm confirmatory trial of tamoxifen alone without surgery for low-risk DCIS of the breast with ER-positive HER2-negative (LORETTA trial: JCOG1505) - Commentary by Sheldon Feldman, MD, FACS
GS2-11 (J): Omission of sentinel lymph node biopsy in T1-2N0 breast cancer with breast-conserving therapy: BOOG 2013-08 trial at 5-year follow-up - Commentary by Prof Norikazu Masuda
GS2-12 (J): A randomized phase III study of radiation doses and fractionation in non-low risk DCIS of the breast: Final 10-year analyses - Commentary by Prof Yutaka Yamamoto
PS4-11-26 (Span): PS4-11-26: First Latin American Consensus on HR+/HER2− Early-Stage Breast Cancer Management - Commentary by Denis Ulises Landaverse, MD
RF4-01: Central Nervous System Outcomes from the Phase III PATINA Trial (AFT-38) - Commentary By: Sarah Sammons, MD
RF4-02: Efficacy Analysis of the Randomized Phase III DETECT V trial: Treatment De-escalation by Omission of Chemotherapy and the Effect of Adding Ribociclib in HER2-positive and Hormone-receptor PMBC - Commentary By: Sarah Sammons, MD
RF4-03: (T-DXd) vs (T-DM1) in patients with high-risk human epidermal growth factor receptor 2-positive (HER2+) primary (BC) with residual invasive disease after neoadjuvant therapy: Interim analysis of DESTINY-Breast05 - Commentary By: Sarah Sammons, MD
RF7-01: Elacestrant in combination with everolimus or abemaciclib in patients with ER+/HER2- locally advanced or metastatic breast cancer (mBC): phase 2 results from ELEVATE, an open-label, umbrella study - Commentary by: Hope S. Rugo, MD
RF7-01 (J): Elacestrant in combination with everolimus or abemaciclib in patients with ER+/HER2- locally advanced or metastatic breast cancer (mBC): phase 2 results from ELEVATE, an open-label, umbrella study - Commentary by: Prof Yutaka Yamamoto
RF7-02: Alpelisib plus fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer after a CDK4/6 inhibitor (EPIK-B5): Phase III, randomized, double-blind, placebo-controlled, multicenter study - Commentary by: Adam Brufsky, MD, PhD
RF7-02 (J): Alpelisib plus fulvestrant for PIK3CA-mutated, HR+/HER2- advanced breast cancer post-CDK4/6i (EPIK-B5) - Commentary by: Prof Yutaka Yamamoto
RF7-03: ESR1m ctDNA dynamics from SERENA-6: phase 3 trial of camizestrant + CDK4/6i for emergent ESR1 mutations during 1L endocrine therapy before progression in HR+/HER2- advanced breast cancer patients - Commentary: Adam Brufsky, MD, PhD
RF7-03: Updated results and ESR1m ctDNA dynamics from SERENA-6: CAMI + CDK4/6i for emergent ESR1m during 1L endocrine therapy in HR+/HER2- ABC - Commentary by: Prof Takayuki Ueno
RF7-04: Gedatolisib (PI3K/AKT/mTOR inhibitor) + fulvestrant ± palbociclib for 2L treatment of HR+/HER2-/PIK3CA-WT advanced breast cancer: updated VIKTORIA-1 phase 3 trial results - Commentary: Adam Brufsky, MD, PhD
RF7-05: Capivasertib plus fulvestrant in hormone receptor-positive (HR+) advanced breast cancer (ABC): exploratory ctDNA analyses from the Phase 3 CAPItello-291 trial - Commentary by: Adam Brufsky, MD, PhD
RF7-05 (J): Capivasertib plus fulvestrant in hormone receptor-positive (HR+) advanced breast cancer (ABC): exploratory ctDNA analyses from the Phase 3 CAPItello-291 trial - Commentary by: Prof Takayuki Ueno
RF7-06: Primary results of Ambre, a randomized phase 3comparing mono-chemotherapy (ct) vs abemaciclib + endocrine therapy (et) in hr+/her2- advanced breast cancer (abc) with high visceral tumor burden - Commentary by: Adam Brufsky, MD, PhD
RF7-07: Adjuvant Palbociclib for ER+ Breast Cancer in the PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): Post-Recurrence Treatment and Overall Survival - Commentary by: Adam Brufsky, MD, PhD
RF7-07 (J): Adjuvant Palbociclib for ER+ Breast Cancer in the PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): Post-Recurrence Treatment and Overall Survival - Commentary by: Commentary by: Prof Takayuki Ueno
SS8-01A: New Drug Approvals for HR+ Metastatic Breast Cancer: Antibody Drug Conjugates - (Dato-DXd) & (T-DXd) - Part 1 - Commentary By: Ruth O'Regan, MD
SS8-01B: New Drug Approvals for HR+ Metastatic Breast Cancer: Antibody Drug Conjugates - (Dato-DXd) & (T-DXd) - Part 2 - Commentary By: Ruth O'Regan, MD
SS8-02: New Drug Approvals for HR+ Metastatic Breast: Imlunestrant (INLURIYO) - Commentary By: Ruth O'Regan, MD
GS3-01 (J): Menopausal Hormone Therapy and the Risk of Breast Cancer in Women with a Pathogenic Variant in BRCA1 or BRCA2 - Commentary by: Prof Hiroko Bando
GS3-01: Menopausal Hormone Therapy and the Risk of Breast Cancer in Women with a Pathogenic Variant in BRCA1 or BRCA2 - Commentary by: Hope S. Rugo, MD
GS3-03: Randomized controlled trial of Young, Empowered & Strong (YES), an mHealth intervention for adolescent and young adult breast cancer survivors - Commentary by: Hope S. Rugo, MD
GS3-04: Effects of Acupuncture vs Sham Acupuncture and Usual Care on Cancer-Related Cognitive Difficulties Among Breast Cancer Survivors: The ENHANCE Randomized Clinical Trial - Commentary by: Hope S. Rugo, MD
GS3-05: Evaluation of the Sensitivity to Endocrine Therapy (SETER/PR) assay to predict benefit from extended endocrine therapy in the NRG/NSABP B-42 trial - Commentary by: Hope S. Rugo, MD
GS3-06: Rb Functions as a Transcriptional Activator of ER Targets Following CDK4/6 Inhibition in Luminal Breast Cancer - Commentary by: Hope S. Rugo, MD
GS3-07: Risk-based breast cancer screening is safe, preferred by women and identifies highest risk individuals: Results from WISDOM 1.0 - Commentary by: Hope S. Rugo, MD
GS3-08: Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): Updated efficacy results from the phase 3 EMBER-3 trial - Commentary by: Hope S. Rugo, MD
GS3-08 (J): Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): Updated efficacy results from the phase 3 EMBER-3 trial - Commentary by: Prof Hiroko Bando
GS3-09: Clinical and biomarker subgroup analysis of evERA Breast Cancer: A Phase III trial of giredestrant plus everolimus in patients with er+, HER2- ABC previously treated with a CDK4/6 inhibitor - Commentary by: Hope S. Rugo, MD
GS3-09 (J): Clinical and biomarker subgroup analysis of evERA Breast Cancer: A Phase III trial of giredestrant plus everolimus in patients with er+, HER2- ABC previously treated with a CDK4/6 inhibitor - Commentary by: Prof Hiroko Bando
RF5-01: Cancer-specific risks associated with germline PALB2 pathogenic variants from a large clinical genetic testing cohort - Commentary by: William Gradishar, MD, FASCO, FACP
RF5-02 (Span): Tbcrc 056: a phase 2 study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the TNBC cohorts - Commentary by: Fernando Petracci, MD, MSc, PhD
RF5-02: Tbcrc 056: a phase 2 study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the TNBC cohorts - Commentary by: William Gradishar, MD, FASCO, FACP
RF5-03: OlympiaN phase 2 results: efficacy and safety of neoadjuvant olaparib monotherapy and olaparib + durvalumab in patients with BRCO mutations and early-stage HER2-negative BC - Commentary by: William Gradishar, MD, FASCO, FACP
RF5-03 (Span) OlympiaN: Phase 2 study of neoadjuvant olaparib ± durvalumab in BRCA+ early HER2- breast cancer - Commentary by Fernando Petracci, MD, MSc, PhD
RF5-04: Germline pathogenic variants in the personalized screening arm of the WISDOM Study: Findings from 23,098 women with no personal history of breast cancer - Commentary by: William Gradishar, MD, FASCO, FACP
RF5-05: RADIOLA phase II trial primary analysis: Predicting olaparib sensitivity in patients with HER2- MBC BRCA1/2, PALB2, RAD51C/D mutations by the RAD51 test: Commentary by: William Gradishar, MD, FASCO, FACP
RF5-06: Pathologic complete response rates (pCR) after the novel HER2 ADC ARX788: Results from the I-SPY2.2 trial - Commentary by: William Gradishar, MD, FASCO, FACP
SS5-03: Early Breast Cancer - Commentary By: William Gradishar, MD
SS5-04: Metastatic Breast Cancer - Commentary By: Janice Tsang, MBBS, MRCP, FRCP, FHKCP
SS6-02: Medical Oncology - Part 1 - Commentary by: William Gradishar, MD, FASCO, FACP
SS6-03: Medical Oncology - Part 2 - Commentary by: William Gradishar, MD, FASCO, FACP
SS6-04: Radiation Oncology - Commentary by: William Gradishar, MD, FASCO, FACP
SS6-05: Surgical Oncology - Commentary by: William Gradishar, MD, FASCO, FACP
GS2-02 - Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine monotherapy for ER+/ HER2- advanced / metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy
GS2-05 - Randomized comparisons of adjuvant exemestane + ovarian function suppression (OFS) vs tamoxifen + OFS vs tamoxifen in premenopausal women with HR+ early breast cancer: update of the TEXT and SOFT trials
GS3-10 - Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDKz, in combination with fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer
GS3-09A - Circulating Tumor Cells-driven choice of first line therapy for HR+ HER2- metastatic breast cancer
GS1-06 - Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial
GS1-09 - Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes
GS3-01A - EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: updated results by duration of prior CDK4/6i in metastatic setting
RF01-01 - SERENA-3: A randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary cancer
RF01-02 - A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy
RF01-03 - PARSIFAL-LONG: Extended follow-up of hormone receptor-positive/HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs letrozole and palbociclib in the PARSIFAL study
RF01-04 - Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification
RF01-06 - Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer
RF01-07 - The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC
RF01-08 - A randomized, open-label phase III trial Evaluating Low-Dose Vs standard-dose Olanzapine with triple Antiemetic therapy for Prevention of highly emetogenic chemotherapy- induced Nausea and vomiting in solid tumors (OLAnzaPiNE)
RF01-01 SERENA-3 - A randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary cancer (China)
RF01-02 - A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy (China)
RF01-03 - PARSIFAL-LONG: Extended follow-up of hormone receptor-positive/HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs letrozole and palbociclib in the PARSIFAL study (China)
RF01-04 - Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification (China)
RF01-06 - Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer (China)
RF01-07 - The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC (China)
RF01-08 - A randomized, open-label phase III trial Evaluating Low-Dose Vs standard-dose Olanzapine with triple Antiemetic therapy for Prevention of highly emetogenic chemotherapy- induced Nausea and vomiting in solid tumors (OLAnzaPiNE) (China)
GS2-05: Early Oncologic Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS: the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25).
GS2-06: Patient Reported Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS in the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25).
GS2-07: No axillary surgery versus axillary sentinel lymph node biopsy in patients with early invasive breast cancer and breast-conserving surgery: Final primary results of the Intergroup-Sentinel-Mamma (INSEMA) trial.
GS2-09: Overweight, obesity and prognosis in 206,904 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database.
ED4-02: Beyond hot flashes: Addressing unmet needs in menopause care after breast cancer Commentary by: Maryam Lustberg, MD, MPH
ED4-04: The Winding Road of MHT: Evidence, Messaging, and an Evidence Informed Approach to Discussing MHT with Women at Elevated Risk - Commentary by: Lisa Larkin, MD, FACP, MSCP, IF
ED4-05: Rethinking menopause and breast cancer: is it time to change practice? Commentary by: Maryam Lustberg, MD, MPH
RF2-01: Prognostic Markers in Residual Tumors after neoadjuvant chemotherapy (NACT) for Early Triple-negative Breast Cancer (TNBC) – a Pooled Analysis from nine Neoadjuvant GBG/AGO-B Trials Commentary by: Joseph Sparano, MD, FACP
RF2-02: Pooled analysis of the BrighTNess, CALGB 40603 (Alliance), and GeparSixto clinical trials identifies the impact of neoadjuvant carboplatin on pCR and survival in early-stage triple-negative breast cancer Commentary by: Joseph Sparano, MD, FACP
RF2-03: Adjuvant epirubicin plus cyclophosphamide followed by taxanes with or without carboplatin for early stage triple-negative breast cancer (RJBC 1501): a randomized controlled phase III trial Commentary by: Joseph Sparano, MD, FACP
RF2-04: Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high-risk early-stage triple-negative breast cancer (CITRINE): a phase 3 randomized trial Commentary by: Joseph Sparano, MD, FACP
RF2-06: Impact of Immune Checkpoint Inhibition (CPI) on Fertility in Young Women with Early Triple-Negative Breast Cancer (TNBC) receiving neoadjuvant Chemotherapy - Commentary by: Joseph Sparano, MD, FACP
RF2-07: Nodal disease burden in patients with clinically node - positive breast cancer undergoing tailored axillary surgery with or without axillary dissection in the neoadjuvant and upfront surgery setting - Commentary by: Joseph Sparano, MD, FACP
ED6-01: Moving on up: ADCs in early-stage breast cancer - Commentary by: Kevin Kalinsky, MD, MS, FASCO
GS1-01: Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer - Commentary by: Matteo Lambertini, MD, PhD
GS1-01 (J): Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer - Commentary by: Prof Eriko Tokunaga
GS1-03: Adjuvant aromatase inhibitor or tamoxifen in patients with hormone receptor-positive/HER2-positive early breast cancer: an exploratory analysis from the ALTTO (BIG 2-06) trial - Commentary by: Matteo Lambertini, MD, PhD
GS1-04 (J): Tumor infiltrating lymphocytes and pathologic complete response in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab - Commentary by: Prof Eriko Tokunaga
GS1-04: Tumor infiltrating lymphocytes and pathologic complete response in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab - Commentary by: Matteo Lambertini, MD, PhD
GS1-05: Prognostic and predictive associations of manual, digital and AI-derived tumor infiltrating lymphocytes-scoring: A retrospective analysis from the Phase III APHINITY trial - Commentary by: Matteo Lambertini, MD, PhD
GS1-06: Circulating tumor DNA (ctDNA) in human epidermal growth factor receptor 2-positive (HER2[+]) Early Breast Cancer (EBC): Translational analysis of PHERGain neoadjuvant tailored treatment study - Commentary by: Kevin Kalinsky, MD, MS, FASCO
GS1-06 (J) : Circulating tumor DNA (ctDNA) in human epidermal growth factor receptor 2-positive (HER2[+]) Early Breast Cancer (EBC): Translational analysis of PHERGain neoadjuvant tailored treatment study - Commentary by: Prof. Shigehira Saji
GS1-08 (J): Multimodal Artificial Intelligence (AI) Models Integrating Image, Clinical, and Molecular Data for Predicting Early and Late Breast Cancer Recurrence in TAILORx - Commentary by: Prof. Shigehira Saji
GS1-08: Multimodal Artificial Intelligence (AI) Models Integrating Image, Clinical, and Molecular Data for Predicting Early and Late Breast Cancer Recurrence in TAILORx - Commentary by: Joseph Sparano, MD, FACP
GS1-09 (J): Sacituzumab Govitecan vs. Chemotherapy as First Therapy After Endocrine Therapy in HR+/HER2- (IHC 0, 1+, 2+/ISH-) Metastatic Breast Cancer: Primary Results From ASCENT-07 Commentary by: Prof. Shigehira Saji
GS1-09: Sacituzumab Govitecan vs. Chemotherapy as First Therapy After Endocrine Therapy in HR+/HER2- (IHC 0, 1+, 2+/ISH-) Metastatic Breast Cancer: Primary Results From ASCENT-07 Commentary by: Kevin Kalinsky, MD, MS, FASCO
GS1-10: Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from Phase III lidERA Breast Cancer trial - Commentary by: Hope S. Rugo, MD
GS1-10 (J): Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from Phase III lidERA Breast Cancer trial - Commentary by: Prof. Shigehira Saji
GS1-11: lidERA and Advent of Adjuvant SERDs - Commentary by: Hope S. Rugo, MD
RF3-02: Gene Expression-based Subtyping of Early Triple-Negative Breast Cancer (TNBC) for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial - Commentary by: Peter Fasching, MD
RF3-04: Tumor-informed circulating tumor DNA analysis to assess molecular residual disease for prognosis and prediction of benefit from palbociclib in the PALLAS trial - Commentary by: Peter Fasching, MD
RF3-07: A Multimodal-Multitask Deep Learning Model Trained in NSABP B-42 and Validated in TAILORx for Late Distant Recurrence Risk in HR+ Early Breast Cancer - Commentary by: Peter Fasching, MD
RF6-01 (J): (T-DXd) vs (T-DM1) in patients with (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy: Interim analysis of DESTINY-Breast05 - Commentary by: Prof Eriko Tokunaga
RF6-01: (T-DXd) vs (T-DM1) in patients with (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy: Interim analysis of DESTINY-Breast05 - Commentary By: Giuseppe Curigliano, MD, PhD
RF6-02: (DB-11) safety: (T-DXd) alone or followed by (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC) - Commentary By: Giuseppe Curigliano, MD, PhD
RF6-02 (J): (DB-11) safety: (T-DXd) alone or followed by (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC) - Commentary by: Prof Eriko Tokunaga
RF6-03: Efficacy and safety of DP303c versus T-DM1 in HER2-positive advanced breast cancer: Interim analysis of a randomized, open-label, phase 3 trial - Commentary By: Giuseppe Curigliano, MD, PhD
RF6-06: DESTINY-Breast11 (DB-11) safety: (T-DXd) alone or followed (THP) vs dose-dense doxorubicin + anthracycline followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC) - Commentary By: Giuseppe Curigliano, MD, PhD
RF6-06 (J): (PROs) in DESTINY-Breast11: (NAT) with (T-DXd) alone or followed by (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC) - Commentary Prof Eriko Tokunaga By:
RF6-06: (PROs) in DESTINY-Breast11: (NAT) with (T-DXd) alone or followed by (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC) - Commentary By: Giuseppe Curigliano, MD, PhD
RF6-07: (T-DXd) + (P) vs (THP) for first-line (1L) treatment of patients with HER2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): patient-reported outcomes (PROs) from the DESTINY-Breast09 study - Commentary By: Giuseppe Curigliano, MD, PhD
GS1-10: Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from Phase III lidERA Breast Cancer trial - Commentary by: Agatha Reyes, MD
GS2-01 (J): More vs less invasive axillary staging in breast cancer patients converting from node-positive to node-negative through neoadjuvant chemotherapy - AXSANA/EUBREAST 3(R) primary analysis
GS2-01 (J): More vs less invasive axillary staging in breast cancer patients converting from node-positive to node-negative through neoadjuvant chemotherapy - AXSANA/EUBREAST 3(R) primary analysis - Prof Norikazu Masuda
GS2-01: More versus less invasive axillary surgical staging procedures in BC patients converting from a clinically node-+ to a clinically node-+ stage through NAC – Commentary by Sheldon Feldman, MD, FACS
GS2-02: Axillary surgery in breast cancer patients with one to three sentinel node macrometastases and breast-conserving therapy: Secondary results of the INSEMA trial - Commentary by Sheldon Feldman, MD, FACS
GS2-02 (J): Axillary surgery in breast cancer patients with one to three sentinel node macrometastases and breast-conserving therapy: Secondary results of the INSEMA trial - Commentary by Prof Norikazu Masuda
GS2-03: Insights of applied radiotherapy among patients undergoing breast-conserving surgery with or without axillary sentinel lymph node biopsy: secondary results from the INSEMA trial - Commentary by Sheldon Feldman, MD, FACS
GS2-03 (J): Insights of applied radiotherapy among patients undergoing breast-conserving surgery with or without axillary sentinel lymph node biopsy: secondary results from the INSEMA trial - Commentary by Prof Norikazu Masuda
GS2-05: Primary Results from the HR+/HER2- Cohort of TBCRC-053: A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer - Commentary by Sheldon Feldman, MD, FACS
GS2-07: Effect of Preoperative Breast MRI Staging on Local Regional Recurrence (LRR) in Early Stage Breast cancer: Alliance A011104/ACRIN 6694 - Commentary by Sheldon Feldman, MD, FACS
GS2-07 (J): Effect of Preoperative Breast MRI Staging on Local Regional Recurrence (LRR) in Early Stage Breast cancer: Alliance A011104/ACRIN 6694 - Commentary by Prof Yutaka Yamamoto
GS2-09 (J): The single-arm confirmatory trial of tamoxifen alone without surgery for low-risk DCIS of the breast with ER-positive HER2-negative (LORETTA trial: JCOG1505) - Commentary by Prof Hiroko Bando
GS2-09: The single-arm confirmatory trial of tamoxifen alone without surgery for low-risk DCIS of the breast with ER-positive HER2-negative (LORETTA trial: JCOG1505) - Commentary by Sheldon Feldman, MD, FACS
GS2-11 (J): Omission of sentinel lymph node biopsy in T1-2N0 breast cancer with breast-conserving therapy: BOOG 2013-08 trial at 5-year follow-up - Commentary by Prof Norikazu Masuda
GS2-12 (J): A randomized phase III study of radiation doses and fractionation in non-low risk DCIS of the breast: Final 10-year analyses - Commentary by Prof Yutaka Yamamoto
PS4-11-26 (Span): PS4-11-26: First Latin American Consensus on HR+/HER2− Early-Stage Breast Cancer Management - Commentary by Denis Ulises Landaverse, MD
RF4-01: Central Nervous System Outcomes from the Phase III PATINA Trial (AFT-38) - Commentary By: Sarah Sammons, MD
RF4-02: Efficacy Analysis of the Randomized Phase III DETECT V trial: Treatment De-escalation by Omission of Chemotherapy and the Effect of Adding Ribociclib in HER2-positive and Hormone-receptor PMBC - Commentary By: Sarah Sammons, MD
RF4-03: (T-DXd) vs (T-DM1) in patients with high-risk human epidermal growth factor receptor 2-positive (HER2+) primary (BC) with residual invasive disease after neoadjuvant therapy: Interim analysis of DESTINY-Breast05 - Commentary By: Sarah Sammons, MD
RF7-01: Elacestrant in combination with everolimus or abemaciclib in patients with ER+/HER2- locally advanced or metastatic breast cancer (mBC): phase 2 results from ELEVATE, an open-label, umbrella study - Commentary by: Hope S. Rugo, MD
RF7-01 (J): Elacestrant in combination with everolimus or abemaciclib in patients with ER+/HER2- locally advanced or metastatic breast cancer (mBC): phase 2 results from ELEVATE, an open-label, umbrella study - Commentary by: Prof Yutaka Yamamoto
RF7-02: Alpelisib plus fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer after a CDK4/6 inhibitor (EPIK-B5): Phase III, randomized, double-blind, placebo-controlled, multicenter study - Commentary by: Adam Brufsky, MD, PhD
RF7-02 (J): Alpelisib plus fulvestrant for PIK3CA-mutated, HR+/HER2- advanced breast cancer post-CDK4/6i (EPIK-B5) - Commentary by: Prof Yutaka Yamamoto
RF7-03: ESR1m ctDNA dynamics from SERENA-6: phase 3 trial of camizestrant + CDK4/6i for emergent ESR1 mutations during 1L endocrine therapy before progression in HR+/HER2- advanced breast cancer patients - Commentary: Adam Brufsky, MD, PhD
RF7-03: Updated results and ESR1m ctDNA dynamics from SERENA-6: CAMI + CDK4/6i for emergent ESR1m during 1L endocrine therapy in HR+/HER2- ABC - Commentary by: Prof Takayuki Ueno
RF7-04: Gedatolisib (PI3K/AKT/mTOR inhibitor) + fulvestrant ± palbociclib for 2L treatment of HR+/HER2-/PIK3CA-WT advanced breast cancer: updated VIKTORIA-1 phase 3 trial results - Commentary: Adam Brufsky, MD, PhD
RF7-05: Capivasertib plus fulvestrant in hormone receptor-positive (HR+) advanced breast cancer (ABC): exploratory ctDNA analyses from the Phase 3 CAPItello-291 trial - Commentary by: Adam Brufsky, MD, PhD
RF7-05 (J): Capivasertib plus fulvestrant in hormone receptor-positive (HR+) advanced breast cancer (ABC): exploratory ctDNA analyses from the Phase 3 CAPItello-291 trial - Commentary by: Prof Takayuki Ueno
RF7-06: Primary results of Ambre, a randomized phase 3comparing mono-chemotherapy (ct) vs abemaciclib + endocrine therapy (et) in hr+/her2- advanced breast cancer (abc) with high visceral tumor burden - Commentary by: Adam Brufsky, MD, PhD
RF7-07: Adjuvant Palbociclib for ER+ Breast Cancer in the PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): Post-Recurrence Treatment and Overall Survival - Commentary by: Adam Brufsky, MD, PhD
RF7-07 (J): Adjuvant Palbociclib for ER+ Breast Cancer in the PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): Post-Recurrence Treatment and Overall Survival - Commentary by: Commentary by: Prof Takayuki Ueno
SS8-01A: New Drug Approvals for HR+ Metastatic Breast Cancer: Antibody Drug Conjugates - (Dato-DXd) & (T-DXd) - Part 1 - Commentary By: Ruth O'Regan, MD
SS8-01B: New Drug Approvals for HR+ Metastatic Breast Cancer: Antibody Drug Conjugates - (Dato-DXd) & (T-DXd) - Part 2 - Commentary By: Ruth O'Regan, MD
SS8-02: New Drug Approvals for HR+ Metastatic Breast: Imlunestrant (INLURIYO) - Commentary By: Ruth O'Regan, MD
GS3-01 (J): Menopausal Hormone Therapy and the Risk of Breast Cancer in Women with a Pathogenic Variant in BRCA1 or BRCA2 - Commentary by: Prof Hiroko Bando
GS3-01: Menopausal Hormone Therapy and the Risk of Breast Cancer in Women with a Pathogenic Variant in BRCA1 or BRCA2 - Commentary by: Hope S. Rugo, MD
GS3-03: Randomized controlled trial of Young, Empowered & Strong (YES), an mHealth intervention for adolescent and young adult breast cancer survivors - Commentary by: Hope S. Rugo, MD
GS3-04: Effects of Acupuncture vs Sham Acupuncture and Usual Care on Cancer-Related Cognitive Difficulties Among Breast Cancer Survivors: The ENHANCE Randomized Clinical Trial - Commentary by: Hope S. Rugo, MD
GS3-05: Evaluation of the Sensitivity to Endocrine Therapy (SETER/PR) assay to predict benefit from extended endocrine therapy in the NRG/NSABP B-42 trial - Commentary by: Hope S. Rugo, MD
GS3-06: Rb Functions as a Transcriptional Activator of ER Targets Following CDK4/6 Inhibition in Luminal Breast Cancer - Commentary by: Hope S. Rugo, MD
GS3-07: Risk-based breast cancer screening is safe, preferred by women and identifies highest risk individuals: Results from WISDOM 1.0 - Commentary by: Hope S. Rugo, MD
GS3-08: Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): Updated efficacy results from the phase 3 EMBER-3 trial - Commentary by: Hope S. Rugo, MD
GS3-08 (J): Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): Updated efficacy results from the phase 3 EMBER-3 trial - Commentary by: Prof Hiroko Bando
GS3-09: Clinical and biomarker subgroup analysis of evERA Breast Cancer: A Phase III trial of giredestrant plus everolimus in patients with er+, HER2- ABC previously treated with a CDK4/6 inhibitor - Commentary by: Hope S. Rugo, MD
GS3-09 (J): Clinical and biomarker subgroup analysis of evERA Breast Cancer: A Phase III trial of giredestrant plus everolimus in patients with er+, HER2- ABC previously treated with a CDK4/6 inhibitor - Commentary by: Prof Hiroko Bando
RF5-01: Cancer-specific risks associated with germline PALB2 pathogenic variants from a large clinical genetic testing cohort - Commentary by: William Gradishar, MD, FASCO, FACP
RF5-02 (Span): Tbcrc 056: a phase 2 study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the TNBC cohorts - Commentary by: Fernando Petracci, MD, MSc, PhD
RF5-02: Tbcrc 056: a phase 2 study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the TNBC cohorts - Commentary by: William Gradishar, MD, FASCO, FACP
RF5-03: OlympiaN phase 2 results: efficacy and safety of neoadjuvant olaparib monotherapy and olaparib + durvalumab in patients with BRCO mutations and early-stage HER2-negative BC - Commentary by: William Gradishar, MD, FASCO, FACP
RF5-03 (Span) OlympiaN: Phase 2 study of neoadjuvant olaparib ± durvalumab in BRCA+ early HER2- breast cancer - Commentary by Fernando Petracci, MD, MSc, PhD
RF5-04: Germline pathogenic variants in the personalized screening arm of the WISDOM Study: Findings from 23,098 women with no personal history of breast cancer - Commentary by: William Gradishar, MD, FASCO, FACP
RF5-05: RADIOLA phase II trial primary analysis: Predicting olaparib sensitivity in patients with HER2- MBC BRCA1/2, PALB2, RAD51C/D mutations by the RAD51 test: Commentary by: William Gradishar, MD, FASCO, FACP
RF5-06: Pathologic complete response rates (pCR) after the novel HER2 ADC ARX788: Results from the I-SPY2.2 trial - Commentary by: William Gradishar, MD, FASCO, FACP
SS5-03: Early Breast Cancer - Commentary By: William Gradishar, MD
SS5-04: Metastatic Breast Cancer - Commentary By: Janice Tsang, MBBS, MRCP, FRCP, FHKCP
SS6-02: Medical Oncology - Part 1 - Commentary by: William Gradishar, MD, FASCO, FACP
SS6-03: Medical Oncology - Part 2 - Commentary by: William Gradishar, MD, FASCO, FACP
SS6-04: Radiation Oncology - Commentary by: William Gradishar, MD, FASCO, FACP
SS6-05: Surgical Oncology - Commentary by: William Gradishar, MD, FASCO, FACP
